TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21166598

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 225
Study: 18359215

Group type: EXPERIMENTAL
Intervention: Portable Oxygen Concentrator (POC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Liquid Oxygen (LO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Compressed Air (CA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: POC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: LO
Number of subjects: 13

Group type: COMPARATOR
Intervention: CA
Number of subjects: 13
Study: 16926261

Group type: EXPERIMENTAL
Intervention: GnRH agonist triptorelin 0.1 mg administered on day 6 after ICSI
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 15523311

Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 198

Group type: COMPARATOR
Intervention: Medical stabilization
Number of subjects: 198
Study: 10742707

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg once daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (celiprolol and placebo)
Number of subjects: 31
Study: 9059768

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes mellitus (NIDDM)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Tropical diabetes
Number of subjects: 550
Study: 8405139

Group type: EXPERIMENTAL
Intervention: Mode I: 20 mg hydrocortisone (HC) at 0700 h and 10 mg HC at 1900 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mode II: 30 mg HC at 0700 h and placebo at 1900 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mode III: Placebo at 0700 h and 30 mg HC at 1900 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mode I
Number of subjects: 14
Study: 3950220

Group type: EXPERIMENTAL
Intervention: High social reinforcement verbal self-instructional (VSI) training group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low social reinforcement verbal self-instructional (VSI) training group
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 24
Study: 30114712

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided thoracic paravertebral block
Number of subjects: 145

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 145
Study: 29364343

Group type: EXPERIMENTAL
Intervention: Encapsulated glass ionomer cement (GIC; Riva Self‐Cure, SDI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hand-mixed glass ionomer cement (GIC)
Number of subjects: 40
Study: 26985905

Group type: COMPARATOR
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 26
Study: 24812492

Group type: EXPERIMENTAL
Intervention: Old 'sticky' tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: New tablet formulations (larger API crystal size, 30% more excipients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 25 mg and 50 mg liquid‐filled hard gelatin capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg reference tablet
Number of subjects: 0
Study: 22192272

Group type: EXPERIMENTAL
Intervention: History of TB
Number of subjects: 23901

Group type: EXPERIMENTAL
Intervention: Past TB
Number of subjects: 23901

Group type: EXPERIMENTAL
Intervention: BCG vaccination during the first year of life
Number of subjects: 23901
Study: 20459368

Group type: EXPERIMENTAL
Intervention: Narrow excision (2 cm margins)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Wide excision (4 cm margins)
Number of subjects: 144
Study: 17664470

Group type: EXPERIMENTAL
Intervention: Oxaliplatin reintroduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin reintroduction > 40%
Number of subjects: 0
Study: 16051519

Group type: EXPERIMENTAL
Intervention: Intervention programme (patient education, consultation with cardiologist, monitoring in Heart Failure Unit)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intervention programme
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study: 11851638

Group type: EXPERIMENTAL
Intervention: S 18326 (0.5 mg h‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: S 18326 (3 mg h‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10703776

Group type: EXPERIMENTAL
Intervention: Intravenous tPA (recombinant alteplase)
Number of subjects: 389
Study: 8963728

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 1350562

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg initially and 1 mg every 4 hr for 24 hr)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Somatostatin (250 micrograms as a bolus and continuous infusion of 250 micrograms/hr for 24 hr)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Somatostatin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Terlipressin and Somatostatin (both groups)
Number of subjects: 33
Study: 2578707

Group type: EXPERIMENTAL
Intervention: 200 mg acyclovir four times a day for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Matching placebo four times a day for 12 weeks
Number of subjects: 31
Study: 30477000

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec plus ipilimumab
Number of subjects: 198
Study: 27717153

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) using 3 MET threshold
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) using individually prescribed MET threshold
Number of subjects: 128
Study: 27422599

Group type: EXPERIMENTAL
Intervention: 30 Hz group - exercise protocol with the platform on
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 Hz group - exercise protocol with the platform on
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group - exercise protocol with the platform off
Number of subjects: 60
Study: 24824197

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 23134891

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (750 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 140
Study: 20729686

Group type: EXPERIMENTAL
Intervention: Fibrin sealing for mesh fixation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mechanical stapling (control)
Number of subjects: 12
Study: 18823461

Group type: EXPERIMENTAL
Intervention: 660 mg of aspirin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16084069

Group type: EXPERIMENTAL
Intervention: Low-dose estrogen replacement therapy (ultralow dose micronized estradiol)
Number of subjects: 16
Study: 12190127

Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted transoral approach
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted submandibular approach
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted treatment with angulated drills and screwdrivers
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Extraoral approach
Number of subjects: 17
Study: 10487502

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dynamic capillaroscopy in obese children
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plasma lipids examination in obese children
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pearson analysis in obese children
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall assessment in obese children
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cutaneous microcirculatory assessment in obese children
Number of subjects: 34
Study: 8598593

Group type: EXPERIMENTAL
Intervention: Intervention schools (CATCH intervention)
Number of subjects: 5106

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 5106
Study: 30328294

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (14,000 U weekly for 8 months)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study: 29121975

Group type: EXPERIMENTAL
Intervention: 1 cup of espresso coffee/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3 cups of espresso coffee/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 cup of espresso coffee plus 2 cocoa-based products containing coffee twice per day
Number of subjects: 21
Study: 25557658

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8mg/kg + methotrexate (MTX) every 4 weeks for 48 weeks
Number of subjects: 103
Study: 23823946

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 0
Study: 21059662

Group type: EXPERIMENTAL
Intervention: Arm sling
Number of subjects: 37
Study: 18679151

Group type: EXPERIMENTAL
Intervention: Micafungin (2 mg/kg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (3 mg/kg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 106
Study: 15583955

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 50 mL/day for 21 days
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 12853587

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin) at a dose of 200 IU per kilogram subcutaneously once daily for five to seven days and a coumarin derivative for six months (target INR 2.5)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Oral anticoagulant (coumarin derivative)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 336
Study: 10725819

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 61
Study: 8967154

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761 (3 times 1 film-coated tablet of 40 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761
Number of subjects: 60
Study: 1737539

Group type: EXPERIMENTAL
Intervention: Two-dose insulin regimen (15% regular, 85% NPH) given before breakfast and dinner
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Four-dose insulin regimen (regular insulin before meals and NPH at 2200)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects (nondiabetic)
Number of subjects: 10
Study: 6202098

Group type: EXPERIMENTAL
Intervention: 160 mg propranolol (Inderal)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31486833

Group type: EXPERIMENTAL
Intervention: EGFR-TKIs plus metformin (500 mg twice a day)
Number of subjects: 139

Group type: COMPARATOR
Intervention: EGFR-TKIs alone
Number of subjects: 139
Study: 29174665

Group type: EXPERIMENTAL
Intervention: Exposure to tobacco advertisements
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Exposure to menthol advertisements
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Higher advertisement exposure
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Increased advertisement exposure (within-subject analysis)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Subsequent time period after increased advertisement exposure
Number of subjects: 56
Study: 26359341

Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 69
Study: 24938504

Group type: EXPERIMENTAL
Intervention: Network treatment (intervention group)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 235
Study: 22252217

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg 3 times/week
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 120
Study: 20846257

Group type: EXPERIMENTAL
Intervention: Oral 600 microg misoprostol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sublingual 600 microg misoprostol
Number of subjects: 64
Study: 19092248

Group type: EXPERIMENTAL
Intervention: CR oxycodone plus pregabalin
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: CR oxycodone
Number of subjects: 409

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 409
Study: 15903381

Group type: EXPERIMENTAL
Intervention: Overhead goal
Number of subjects: 35

Group type: COMPARATOR
Intervention: No overhead goal
Number of subjects: 35
Study: 12915604

Group type: EXPERIMENTAL
Intervention: High-dose IV IL-2 (720,000 U/kg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Low-dose IV IL-2 (72,000 U/kg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Low-dose daily subcutaneous IL-2
Number of subjects: 400
Study: 10485635

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75 or 150 mg/day)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg/day in 3 divided doses)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 8738759

Group type: EXPERIMENTAL
Intervention: R-methadone (tablets)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: S-methadone (tablets)
Number of subjects: 10
Study: 2016246

Group type: EXPERIMENTAL
Intervention: Exposure therapy for 3 or 6 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exposure therapy (6 weeks vs. 3 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exposure therapy homework compliance
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Initial severity of illness
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Depression levels
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: General anxiety levels
Number of subjects: 34
Study: 7127999

Group type: EXPERIMENTAL
Intervention: Sustained-release furosemide (FR, 60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional furosemide tablet (F, 40 mg)
Number of subjects: 12
Study: 29743136

Group type: EXPERIMENTAL
Intervention: Economic strengthening plus family coaching component (TU + arm)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Economic intervention utilizing the Graduation approach (Trickle Up/TU arm)
Number of subjects: 360
Study: 26729582

Group type: EXPERIMENTAL
Intervention: CsA + AZA (n = 53)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CsA + MMF (n = 53)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CsA monotherapy (n = 98)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CsA + AZA
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CsA + MMF
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CsA monotherapy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: AZA
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 204
Study: 25304142

Group type: EXPERIMENTAL
Intervention: Ultrasonic bone surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 200
Study: 21927844

Group type: EXPERIMENTAL
Intervention: GFLX-containing regimen (gatifloxacin)
Number of subjects: 27

Group type: COMPARATOR
Intervention: CAM-containing regimen (clarithromycin)
Number of subjects: 27
Study: 20127127

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 31
Study: 18396071

Group type: EXPERIMENTAL
Intervention: Fluoropassiv patch
Number of subjects: 87

Group type: COMPARATOR
Intervention: Venous patch
Number of subjects: 87
Study: 15632665

Group type: EXPERIMENTAL
Intervention: Prototype carbohydrate‐electrolyte drink (PCE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Commercially available carbohydrate‐electrolyte drink (CCE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Water (neutral control)
Number of subjects: 19
Study: 12873261

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 400 mg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 10925929

Group type: EXPERIMENTAL
Intervention: EMLA cream (20 g) applied perioperatively and daily for 4 days post-surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 8677990

Group type: EXPERIMENTAL
Intervention: Mesalamine suspension enema (4 g at night)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral sulfasalazine (1 g four times a day)
Number of subjects: 37
Study: 1986150

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy group - three monthly doses of 500 micrograms of TAA emulsified with CFA
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nonspecific immunotherapy group - three monthly doses of CFA emulsified in saline
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group - no treatment
Number of subjects: 85
Study: 6653642

Group type: EXPERIMENTAL
Intervention: Propranolol (P) therapy
Number of subjects: 13
Study: 30637907

Group type: EXPERIMENTAL
Intervention: 1Hz MSCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 30232949

Group type: EXPERIMENTAL
Intervention: Active devices that applied moisture to the external ear
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo devices that contained no moisture
Number of subjects: 8
Study: 28178109

Group type: EXPERIMENTAL
Intervention: Risk reduction counseling and condoms provided throughout the trial
Number of subjects: 4843
Study: 26519909

Group type: EXPERIMENTAL
Intervention: Personal reminders for vaccination
Number of subjects: 0
Study: 23153388

Group type: EXPERIMENTAL
Intervention: Hypnosis treatment (5 sessions over 2 months)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 59
Study: 21516330

Group type: COMPARATOR
Intervention: Arm cycling at 1 Hz with contralateral arm at rest
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arm cycling at 1 Hz with contralateral arm cycling at 1 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arm cycling at 1 Hz with contralateral arm cycling at 2 Hz
Number of subjects: 12
Study: 18285645

Group type: EXPERIMENTAL
Intervention: Standing aid (Aid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No aid (No aid)
Number of subjects: 12
Study: 17163277

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Ziprasidone 80mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Ziprasidone 160mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Average dose of Ziprasidone
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 14723254

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 54
Study: 11034035

Group type: EXPERIMENTAL
Intervention: Hamulus fracture during palatoplasty (85 patients)
Number of subjects: 173

Group type: COMPARATOR
Intervention: No hamulus fracture during palatoplasty (76 patients)
Number of subjects: 173
Study: 9378833

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 143

Group type: COMPARATOR
Intervention: Stannous fluoride toothpaste
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 143

Group type: COMPARATOR
Intervention: Triclosan/zinc citrate toothpaste
Number of subjects: 143
Study: 8466062

Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3541946

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate inhaled as a dry-powder, 400 micrograms twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional aerosol, 100 micrograms four times daily
Number of subjects: 16
Study: 29683755

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally twice daily from day 0 to 5
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 26558724

Group type: EXPERIMENTAL
Intervention: MVA-B vaccine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 27687887

Group type: EXPERIMENTAL
Intervention: Salt-reduction and efficacy-maintenance program
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Salt-reduction training
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 22748952

Group type: EXPERIMENTAL
Intervention: Third-generation thermal uterine balloon therapy (UBT) system with no post-procedure curettage (PPC)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Third-generation thermal uterine balloon therapy (UBT) system with post-procedure curettage (PPC)
Number of subjects: 250

Group type: COMPARATOR
Intervention: First-generation UBT system
Number of subjects: 250
Study: 19570664

Group type: EXPERIMENTAL
Intervention: Low calorie (LF-LC) (-2MJ)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low calorie with 10% polyunsaturated fatty acids (LF-PUFA-LC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Isocaloric with 10% polyunsaturated fatty acids (LF-PUFA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Isocaloric (LF)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study: 18769356

Group type: EXPERIMENTAL
Intervention: Episodic antiretroviral therapy
Number of subjects: 883

Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy
Number of subjects: 883
Study: 15730602

Group type: EXPERIMENTAL
Intervention: Infasurf (exogenous surfactant)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 42